Skip to main content
    P

    Purple Biotech (PPBT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.23
    +0.00 (+0.00%)

    Market Cap: $2.00M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    58%(19/33)
    Avg Surprise
    -222.67%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-2.88
    Range$-2.88 - $-2.88
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.42-585.7%
    60d ago$-1.73-66.5%
    30d ago$-1.73-66.5%
    7d ago$-1.73-66.5%
    Current$-2.88
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.49
    Range$-1.49 - $-1.49
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.49---
    Sep 26EST
    		-$-2.88---
    Jun 26
    Reported Aug 7
    		$1.07$-0.98+209.18%Beat+126.8%
    Mar 26
    Reported May 15
    		$-2.33$-0.38-512.45%Miss-1261.8%
    Dec 25
    Reported Mar 13
    		$-6.16$-3.40-81.18%Miss-127.3%
    Sep 25
    Reported Nov 14
    		$2.90$-2.60+211.54%Beat+121.2%
    Jun 25
    Reported Aug 6
    		$-4.00$-2.10-90.48%Miss+74.8%
    Mar 25
    Reported May 21
    		$-0.17$0.00N/ABeat+99.4%
    Dec 24
    Reported Mar 10
    		$-2.71$-2.20-23.18%Miss+95.7%
    Sep 24
    Reported Nov 15
    		$-13.67$-0.60-2178.33%Miss+67.5%
    Jun 24
    Reported Aug 16
    		$-15.88$-26.00+38.92%Beat+64.1%
    Mar 24
    Reported May 21
    		$-30.26$-30.00-0.87%Miss+27.3%
    Dec 23
    Reported Mar 5
    		$-63.14$-34.00-85.71%Miss-7.2%
    Sep 23
    Reported Nov 21
    		$-42.02$-44.00+4.50%Beat+7.8%
    Jun 23
    Reported Aug 22
    		$-44.22$-50.00+11.56%Beat-22010.0%
    Mar 23
    Reported May 16
    		$-41.60$-70.00+40.57%Beat-10048.8%
    Dec 22
    Reported Feb 8
    		$-58.90$-50.00-17.80%Miss-23460.0%
    Sep 22
    Reported Nov 8
    		$-45.56$-42.00-8.48%Miss-26700.0%
    Jun 22
    Reported Aug 4
    		$-0.20$-0.20+0.00%Beat-
    Mar 22
    Reported May 12
    		$-0.41N/AN/ABeat+99.5%
    Dec 21
    Reported Feb 9
    		$-0.25N/A+87.50%Beat-2400.0%
    Sep 21
    Reported Dec 1
    		$-0.17$-0.01-1600.00%Miss-1600.0%
    Jun 21
    Reported Aug 5
    		$0.00N/A+100.00%Beat+100.0%
    Mar 21
    Reported Jun 10
    		$-76.00$-2.00-3700.00%Miss-189900.0%
    Dec 20
    Reported Mar 2
    		$-0.01$-0.01+0.00%Beat+96.7%
    Sep 20
    Reported Dec 2
    		$-0.01$-0.01+0.00%Beat-
    Jun 20
    Reported Aug 11
    		$-0.01N/A+90.00%Beat-
    Mar 20
    Reported Jun 3
    		$-0.04$0.00N/AMiss+78.9%
    Dec 19
    Reported Feb 11
    		$-0.30$-0.09-233.33%Miss+99.0%
    Sep 19
    Reported Nov 27
    		$0.00N/A+100.00%Beat-
    Jun 19
    Reported Aug 8
    		$0.00N/A+100.00%Beat+100.0%
    Mar 19
    Reported May 29
    		$-0.19$-0.19+0.00%Beat-90.0%
    Dec 18
    Reported Feb 7
    		$-30.00$-20.00-50.00%Miss+0.0%
    Sep 18
    Reported Nov 28
    		$0.00N/A+100.00%Beat-
    Jun 18
    Reported Aug 29
    		$-0.01N/A+90.00%Beat-
    Mar 18
    Reported May 5
    		$-0.10$-0.10+0.00%Beat-
    Dec 17
    Reported Mar 5
    		$-30.00$-20.00-50.00%Miss-
    Dec 16
    Reported Mar 17
    		$0.00N/A+100.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.27EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-111.10%ROIC-156.20%
    Financial Health
    Debt/Equity0.01xInterest Coverage-360.69x
    Current Ratio3.70xQuick Ratio3.70x
    Trading Statistics
    Beta-0.55Avg Volume37.95K
    52-Week High$14.1052-Week Low$1.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.40
    SMA 20$1.44
    SMA 50$1.56
    SMA 200$3.33
    EMA 10$1.37
    EMA 20$1.44
    EMA 50$1.58
    EMA 200$4.12

    MACD

    Line: -0.08Signal: -0.06Hist: -0.02

    ADX

    ADX: 15.9+DI: 12.2-DI: 24.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$1.62

    Bollinger Bands

    Upper Band$1.63
    Lower Band$1.26
    %B Position2560%(Upper)
    Band Width-0.07

    RSI (14-Day)

    Neutral
    30.1

    Momentum Oscillators

    Stoch %K11.6
    Stoch %D16.4
    Williams %R-90.2
    ROC (10d)-19.1%
    Momentum-0.29
    CCI (20d)-204.4
    MFI (14d)32.3

    Volatility Measures

    ATR (14d)$0.14(11.1%)
    StdDev (20d)0.09
    Hist Vol58.1%(High)

    Volume Flow

    VWAP$1.26
    OBV379.9M
    AD Line30.5B
    CMF (20d)-0.031

    Volume Metrics

    Avg Vol (20d)33.6K
    Vol Ratio1.2x
    VWMA (20d)$1.43

    Pivot Points

    R3$1.50
    R2$1.44
    R1$1.34
    Pivot Point$1.28
    S1$1.18
    S2$1.12
    S3$1.02

    Advanced Oscillators

    TSI-25.07
    Ultimate Osc45.2
    KST-129.66

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/A$64,823$53,331$58,272$48,009$44,766$40,000$49,000$48,999N/A$48,517$50,000
    Gross ProfitN/A$-64,823$-53,331$-58,272$-48,009$-44,766$-40,000$-49,000$-48,999N/A$-48,517$-50,000
    Operating Expenses$1.30M$2.25M$23.45M$1.37M$1.24M$1.41M$976,000$2.13M$3.46M$4.47M$6.29M$5.75M
    R&D$702,000$1.23M$1.83M$587,000$553,000$760,000$458,000$1.35M$2.39M$3.42M$5.30M$4.59M
    SG&A$597,000$1.02M$873,000$780,000$683,000$646,000$310,000$785,000$865,000$1.04M$630,000$1.16M
    Operating Income$-1,299,000$-2,251,000$-23,445,000$-1,367,000$-1,236,000$-1,406,000$-1,016,000$-2,133,000$-3,458,000$-4,466,000$-6,334,539$-5,747,000
    Interest Income$79,000$20,000$1,000$123,000$73,000$54,000$152,000$130,000$121,000$702,000$635,000$708,000
    Interest Expense$9,000$31,000$23,000$5,000$0$35,000$511,000$511,000$24,000$17,000$1.99M$16,000
    Income Before Tax$441,000$-89,000$-23,642,000$-1,305,000$-1,089,000$-456,000$-415,000$-668,000$-2,415,000$-3,781,000$-4,911,365$-5,055,000
    Income Tax Expense$0$0$0$0$0$0$0$0$-9,999$683,000$1.21M$689,000
    Net Income$441,000$-86,000$-23,545,000$-1,303,000$-1,085,000$-453,000$-410,000$-663,000$-2,405,000$-3,762,000$-4,880,031$-5,036,000
    EBITDA$520,000$7,000$-23,566,000$-1,242,000$-1,042,000$-376,000$-886,000$-108,000$-2,342,000$-3,716,000$-6,286,022$-4,989,000
    EBIT$450,000$-58,000$-23,619,000$-1,300,000$-1,089,000$-421,000$-926,000$-157,000$-2,391,000$-3,764,000$-6,334,539$-5,039,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PPBT

    News

    A former CEO returns as interim chief at Purple Biotech (PPBT) as Gil Efron changes roles.

    Purple Biotech (PPBT) has appointed Isaac Israel as Interim Chief Executive Officer, effective October 5, 2026. Israel previously served as CEO from 2012 to 2022 and has been a director since 2012. Gil Efron...

    Stock Titan•10/5/26•Neutral

    PPBT Technical Analysis & Stock Price Forecast

    This article provides a detailed technical analysis of Purple Biotech Ltd (PPBT), indicating a "Strong Sell" consensus based on various indicators. It covers moving averages, momentum oscillators like RSI and MACD...

    Intellectia AI•9/26/26•Bearish

    Purple Biotech : 6K-New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies

    Purple Biotech announced that it received a U.S. patent allowance for its CAPTN-3 modular platform, which is designed for next-generation multispecific antibodies. This patent covers tri-specific antibody constructs...

    marketscreener.com•9/3/26•Bullish

    Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

    Purple Biotech has reached a significant manufacturing milestone for IM1240, a tri-specific antibody developed using its CAPTN-3 platform. The company has achieved commercially viable yield for IM1240...

    Barchart.com•8/28/26•Bullish

    Purple Biotech (PPBT) sees 26.5M shares reported owned by broker-dealer group

    G1 Execution Services, LLC and Susquehanna Securities, LLC have jointly reported beneficial ownership of 26,532,000 shares of Purple Biotech Ltd. (PPBT)...

    Stock Titan•8/14/26•Neutral

    PPBT Valuation and Fair Value

    P/E
    -0.3x
    P/B
    1.1x
    See GNG's fair value

    PPBT Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -156.2%
    ROE
    -111.1%

    PPBT Competitors

    CompanyTicker
    NewGenIvf Group Limited Class A Ordinary SharesNIVF
    Nexgel IncNXGL
    Beyond Air IncXAIR
    Genprex IncGNPX
    BioRestorative Therapies IncBRTX
    Oragenics IncOGEN
    Clearside Biomedical IncCLSD
    Curis IncCRIS

    Sector: Healthcare

    PPBT Bull Case vs Bear Case

    Bear case

    • PPBT beat EPS estimates in 25.0% of its last 8 reported quarters.

    PPBT Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -352.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-2.88
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About PPBT

    Does PPBT pay dividends?

    Purple Biotech (PPBT) does not currently pay a regular dividend.

    What is PPBT's market cap?

    Purple Biotech (PPBT) has a market capitalization of $2.00M with a current stock price of $1.23.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In